Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations

Journal of Thoracic Oncology

Volumn 11, Issue 7, 2016, Pages 1140-1152

  Chen, Yen Fu ^a,b   Hsieh, Min Shu ^a,b   Wu, Shang Gin ^a,b   Chang, Yih Leong ^a,b   Yu, Chong Jen ^a,b   Yang, James Chih Hsin ^a,c   Yang, Pan Chyr ^a,b   Shih, Jin Yuan ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

EGFR mutation; EML4 ALK fusion; KRAS mutation; Pemetrexed based therapy; ROS1 fusion

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CISPLATIN; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PEMETREXED; PROTEIN TYROSINE KINASE; ROS PROTOONCOGENE 1; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EML4-ALK FUSION PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN P21; ROS1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; DRUG EFFICACY; EAST ASIAN; FEMALE; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; PHARMACOGENETICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING; TREATMENT RESPONSE; ADENOCARCINOMA; CHEMISTRY; COMPARATIVE STUDY; GENETICS; LUNG NEOPLASMS; MORTALITY; MUTATION; RETROSPECTIVE STUDY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; GENE FUSION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; ONCOGENE PROTEINS, FUSION; PEMETREXED; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE;

EID: 84978291112     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.03.022     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
3. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566.
4. Cardarella S, Johnson BE. The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med. 2013;188:770-775.
5. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.
6. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multi-centre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-246.
7. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non- small cell lung cancer. N Engl J Med. 2010;363:1693-1703.
8. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385-2394.
9. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signalling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190-1203.
10. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863-870.
11. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18:378-381.
12. Davies KD, Le AT, Theodoro M, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012;18:4570-4579.
13. Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1-positive tumours in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;8:4449-4457.
14. Chen YF, Hsieh MS, Wu SG, et al. Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. J Thorac Oncol. 2014;9:1171-1179.
15. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1- rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963-1971.
16. Mazières J, Zalcman G, Crinò L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015;33:992-999.
17. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Non-small-cell lung cancer. Version 4. 2015, http://www.nccn.org 2015. Accessed February 2015.
18. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo [2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997;57: 1116-1123.
19. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-3551.
20. Grønberg BH, Bremnes RM, Fløtten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:3217-3224.
21. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22: 1589-1597.
22. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374:1432-1440.
23. Wu SG, Yang CH, Yu CJ, et al. Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer. 2011;72:333-339.
24. Jiang X, Yang B, Lu J, et al. Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes. Tumour Biol. 2015;36: 861-869.
25. Camidge DR, Kono SA, Lu X, et al. Anaplastic lymphoma kinase gene rearrangements in non-small-cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol. 2011;6:774-780.
26. Lee JO, Kim TM, Lee SH, et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small-cell lung cancer. J Thorac Oncol. 2011;6:1474-1480.
27. Shaw AT, Varghese AM, Solomon BJ, et al. Pemetrexedbased chemotherapy in patients with advanced, ALKpositive non-small-cell lung cancer. Ann Oncol. 2013;24:59-66.
28. Liang Y, Wakelee HA, Neal JW, et al. Relationship of driver oncogenes to long-term pemetrexed response in non-small-cell lung cancer. Clin Lung Cancer. 2015;16:366-373.
29. Park S, Park TS, Choi CM, et al. Survival benefit of pemetrexed in lung adenocarcinoma patients with anaplastic lymphoma kinase gene rearrangements. Clin Lung Cancer. 2015;16:e83-e89.
30. Pan Y, Zhang Y, Li Y, et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer. 2014;84:121-126.
31. Kim HR, Lim SM, Kim HJ, et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol. 2013;24:2364-2370.
32. Riess JW, Padda SK, Bangs CD, et al. A case series of lengthy progression-free survival with pemetrexedcontaining therapy in metastatic non-small-cell lung cancer patients harboring ROS1 gene rearrangements. Clin Lung Cancer. 2013;14:592-595.
33. Chen CY, Chang YL, Shih JY, et al. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer. 2011;74:132-138.
34. Lee SH, Noh KB, Lee JS, et al. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. Lung Cancer. 2013;81:102-108.
35. Wang L, Wang R, Pan Y, et al. The pemetrexedcontaining treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis. BMC Cancer. 2014;14:205.
36. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multi-Disciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol. 2011;6:244-285.
37. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, eds. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press, 2004.
38. Rami-Porta R, Ball D, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007;2:593-602.
39. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
40. Centers for Disease Control and Prevention. Cigarette smoking among adults - United States, 2006. MMWR Morb Mortal Wkly Rep. 2007;56:1157-1161.
41. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12:175-180.
42. Go H, Kim DW, Kim D, et al. Clinico-pathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm. J Thorac Oncol. 2013;8:1445-1450.
43. Tsai TH, Su KY, Wu SG, et al. RNA is favorable for analyzing EGFR mutations in malignant pleural effusion of lung cancer. Eur Respir J. 2011;39:677-684.
44. Tsai TH, Yang CY, Ho CC, et al. Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. Lung Cancer. 2013;82:420-425.
45. Righi L, Papotti MG, Ceppi P, et al. Thymidylate synthase but not excision repair cross complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol. 2010;28:1534-1539.
46. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
47. Warth A, Penzel R, Lindenmaier H, et al. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. Eur Respir J. 2014;43:872-883.
48. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol. 2002;26:767-773.
49. Zhu Q, Zhan P, Zhang X, et al. Clinicopathologic characteristics of patients with ROS1 fusion gene in non- small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2015;4:300-309.
50. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327-3334.
51. Soria JC, Wu YL, Nakagawa K, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16:990-998.
52. Giovannetti E, Lemos C, Tekle C, et al. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small cell lung cancer cells. Mol Pharmacol. 2008;73:1290-1300.